“How can I trust them?”: Inside Black Americans’ very justified vaccine skepticism

On Wednesday, the United States reported over 2,800 deaths due to coronavirus in a single day. This grim figure marks the highest single-day death count ever recorded in the U.S. In November alone, the U.S. reported over 4 million coronavirus cases, more than what most countries have seen all year. With the federal government failing on multiple levels, some Americans are looking to one new savior: a coronavirus vaccine.

This week, the United Kingdom became the first country to approve U.S.-based Pfizer and its German partner BioNTech’s vaccine, with plans to roll out shots next week. While the U.S. hasn’t reached a decision as fast, an advisory committee of the Food and Drug Administration will meet on Dec. 10 to determine whether or not it will grant emergency approval to Pfizer. The decision will then go on to the FDA itself. Along with Pfizer’s vaccine, scientists are reviewing data from Moderna.

Talk of a vaccine is one thing. Watching as it becomes a reality is another, and the thought brings renewed hope for some — but not necessarily the communities most impacted by the pandemic. Per the COVID Racial Data Tracker, part of The Atlantic‘s COVID Tracking Project, Black people nationwide are dying at two times the rate of white people, for a current total of 47,704 Black lives lost. Black people account for nearly 20% of deaths in the U.S. where race is known.

Vaccines offer hope for end to pandemic, but brutal months lie ahead

Washington Post logo

Coronavirus vaccines are poised to be approved and distributed in the coming weeks in the United States, but that promising news comes amid record levels of infections and hospitalizations, with experts warning that the most brutal period of the pandemic lies ahead.

This is a split-screen moment: Progress on vaccines means people can now plausibly talk about what they will do when the pandemic is over. But with new infections topping 212,000 Thursday — another daily record, topping one set Wednesday — it won’t be over in a snap. This remains a dismal slog.

“The vaccine has not come in time to do much about the winter wave,” said Christopher Murray, director of the University of Washington’s Institute for Health Metrics and Evaluation. “Vaccination is coming too late even if we do a really great job of scale-up. It’s coming too late to do much by March 1, or really by April 1.” Only at that point, he added, will the widespread distribution of vaccines begin to crush the virus. Continue reading.

Health-care workers, nursing home residents should get coronavirus vaccine first, panel says

Washington Post logo

NOTE: This article is provided free to all by The Washington Post.

An estimated 20 million health-care workers should get top priority for a vaccine to keep the nation’s hospitals and clinics functioning, an advisory panel to the Centers for Disease Control and Prevention recommended Tuesday.

Biotechnology company Moderna has requested emergency authorization of its experimental vaccine, which means the U.S. government potentially could start distributing two vaccines in the next few weeks. View the post here.

Moderna to apply for emergency use authorization for COVID-19 vaccine candidate on Monday

The Hill logo

Moderna announced that it will apply for emergency use authorization from the U.S. Food and Drug Administration (FDA) for its COVID-19 vaccine candidate on Monday.

The company said in a statement that testing showed its vaccine candidate was 94.1 percent effective in preventing COVID-19 and was 100 percent effective against severe COVID-19.

It also said “no serious safety concerns” have been identified to date. Some trial participants have experienced reactions like pain at the site of the injection or fatigue. Continue reading.

6.4 million COVID-19 vaccine doses expected to be shipped to states by mid-December

The Hill logo

States will begin receiving the first doses of COVID-19 vaccines in mid-December, but will make their own determinations on who will be first in line for a shot. 

An estimated 6.4 million doses of Pfizer’s vaccine will be distributed to states and territories by mid-December, assuming it receives Food and Drug Administration (FDA) authorization by that point, Operation Warp Speed officials told reporters Tuesday. 

State officials were notified Friday how many doses they should expect to receive in the initial distribution, and they will make their own decisions about who will be prioritized for the first doses. Continue reading.

Pfizer: COVID-19 vaccine testing shows 95 percent efficacy, emergency use application planned ‘within days’

The Hill logo

Pfizer on Wednesday announced that final data on its coronavirus vaccine candidate showed it to be 95 percent effective, adding that the company would be applying for Federal Drug Administration (FDA) emergency authorization “within days.” 

Pfizer said that the vaccine candidate, developed with German company BioNTech, is 95 percent effective “against COVID-19 beginning 28 days after the first dose.” 

The company last week said that interim data revealed its vaccine to be 90 percent effective.  Continue reading.

Moderna says coronavirus vaccine is 94.5 percent effective

The Hill logo

Moderna announced Monday morning that its coronavirus vaccine candidate was 94.5 percent effective in an interim analysis, a second promising data point in the push for a successful vaccine.

The announcement comes one week after Pfizer announced its vaccine was over 90 percent effective, meaning there are now two vaccines with very high levels of efficacy in interim analyses of clinical trial data.

Moderna based its data on a large clinical study involving 30,000 volunteers, half of whom received two doses of the vaccine over a 28-day period. There were 95 cases of coronavirus recorded among participants, with only 5 of them in the group receiving the vaccine. Continue reading.

Pfizer CEO says he would’ve released vaccine data before election if possible

Axios logo

Pfizer on Monday announced that its COVID-19 vaccine has proven effective in over 90% of previously uninfected people, and added that it could have 50 million doses available by year-end. 

Axios Re:Cap talks to Pfizer CEO Albert Bourla about vaccine data, distribution, politics, and how he reacted upon receiving the news.

Continue reading.

Trump’s messy attempt to clean up unwelcome coronavirus vaccine news

Washington Post logo

President Trump is putting a lot of his reelection hopes on one thing: the imminent arrival of a coronavirus vaccine that he and his administration can take credit for.

We got a glimpse Wednesday of just how dependent the president is on convincing Americans a vaccine is coming to end this pandemic in months.

Earlier in the day, a top public health official in his administration said something that doesn’t jibe with that. Centers for Disease Control and Prevention DirectorRobert Redfield said that even if a vaccine were ready and approved by this fall or winter, it wouldn’t be ready to be widely distributed to Americans until spring or summer 2021. Continue reading.

Experts fear political pressure on COVID-19 vaccine

The Hill logoPublic health experts are raising red flags that the Trump administration could exert political pressure on the Food and Drug Administration (FDA) to approve a COVID-19 vaccine before one is ready.

President Trump, searching for a political win just over three months from the election, has latched onto the push for developing a vaccine in record time and promoted it in a number of recent appearances.

Trump spoke optimistically of the prospects for a vaccine during a visit to a biotech facility in North Carolina on Monday, despite experts cautioning one may not be widely available for another year. Continue reading.